Oak Therapeutics Competitors

ImmunoGen is now part of AbbVie. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. For more information about AbbVie, please visit us at www.abbvie.com. Follow AbbVie on LinkedIn for future updates. Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.

NeuroRx is dedicated to working with the pharmaceutical industry to facilitate clinical trials of new drugs for multiple sclerosis (MS) and other neurological diseases. NeuroRx provides professional management of all MRI-related study activities and promptly delivers precise MRI outcome measurements that are performed in a regulatory compliant environment. We are specialized in logistics of scan handling and tracking and can provide this service exclusively, if needed. NeuroRx uses advanced image analysis techniques to provide precise outcome data that maximize study power. Images are corrected for inhomogeneity and co-registered for perfect re-alignment and increased precision. Analyses are conducted in 3D, rather than on slices, so that information can be properly related to structures that span multiple slices. Customized automatic segmentation techniques are combined with expert supervision to maximize the precision of outcome measures related to both lesional and non-lesional pathology, as well as brain volume changes (atrophy).